DILANTIN

This brand name is authorized in United States. It is also authorized in Australia, Canada, France, Hong Kong SAR China, Israel, New Zealand, Singapore.

Active ingredients

The drug DILANTIN contains one active pharmaceutical ingredient (API):

1	Phenytoin UNII 6158TKW0C5 - PHENYTOIN
	Phenytoin is effective in various animal models of generalised convulsive disorders, reasonably effective in models of partial seizures but relatively ineffective in models of myoclonic seizures. It appears to stabilise rather than raise the seizure threshold and prevents spread of seizure activity rather than abolish the primary focus of seizure discharge.
	Read more about Phenytoin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DILANTIN Extended-release capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)
DILANTIN INFATABS Chewable tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
DILANTIN-125 Oral suspension	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N03AB02	Phenytoin	N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AB Hydantoin derivatives
Discover more medicines within N03AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1249R, 1873N, 1874P, 2692Q
CA	Health Products and Food Branch	00022772, 00022780, 00023442, 00023450, 00023698
FR	Base de données publique des médicaments	62436200
HK	Department of Health Drug Office	07909, 07913, 19932, 65291
IL	מִשְׂרַד הַבְּרִיאוּת	433
NZ	Medicines and Medical Devices Safety Authority	743, 744, 747, 748
SG	Health Sciences Authority	06056P, 09208P, 13114P
US	FDA, National Drug Code	0071-0007, 0071-0369, 0071-2214, 0071-3740, 50090-0029, 70518-0980